Cadrenal Therapeutics, Inc. Forecasted to Earn Q3 2024 Earnings of ($2.18) Per Share (NASDAQ:CVKD)

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Research analysts at Zacks Small Cap issued their Q3 2024 EPS estimates for Cadrenal Therapeutics in a research note issued on Monday, September 16th. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings per share of ($2.18) for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($6.00) per share. Zacks Small Cap also issued estimates for Cadrenal Therapeutics’ Q4 2024 earnings at ($2.18) EPS, FY2024 earnings at ($8.17) EPS, FY2025 earnings at ($2.90) EPS and FY2026 earnings at ($2.20) EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $0.20 price target on shares of Cadrenal Therapeutics in a research note on Thursday, June 6th.

Cadrenal Therapeutics Trading Down 6.4 %

Shares of NASDAQ:CVKD opened at $11.21 on Wednesday. Cadrenal Therapeutics has a 52 week low of $5.40 and a 52 week high of $32.55. The company has a market capitalization of $179.45 million, a price-to-earnings ratio of -36.16 and a beta of 1.74.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($2.25) EPS for the quarter, beating the consensus estimate of ($19.04) by $16.79.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.